New Pure Play Novartis Vows To Up Its Game – With Help From In-House Challenger Ronny Gal
‘US First’ Policy To Boost Growth
Having finally confirmed the Sandoz spin-off, Novartis will become a 'pure play' pharma company and focus on picking bigger blockbuster winners from both internal and external pipelines. CEO Vas Narasimhan talked details at an investor day in Basel.
